Hutchmed's Fanregratinib Receives Priority Review Status From China's NMPA for Advanced Liver Cancer Treatment

Hutchmed China Ltd. has achieved a significant regulatory milestone as China’s National Medical Products Administration (NMPA) has granted priority review status to its New Drug Application for fanregratinib (HMPL-453), an oral therapeutic agent designed to address advanced and metastatic intrahepatic cholangiocarcinoma in patients with specific FGFR 2 fusion or rearrangement markers who have undergone prior systemic treatment.

Understanding the Disease Landscape

Intrahepatic cholangiocarcinoma represents a particularly aggressive form of liver malignancy originating from the biliary epithelium. This disease category comprises 8.2-15.0% of all primary liver cancers, positioning it as the second most prevalent hepatic malignancy behind hepatocellular carcinoma. Patients diagnosed with cholangiocarcinoma typically face more challenging long-term survival outcomes compared to other liver cancer types, underscoring the critical need for innovative treatment options.

Clinical Evidence Supporting the Application

The regulatory submission is anchored by robust clinical data derived from a single-arm, multi-center, open-label Phase II registration study conducted in China. The trial successfully achieved its primary efficacy endpoint—objective response rate—with additional measures strengthening the evidence base. Secondary outcome assessments, including progression-free survival duration, overall disease control rate, sustained response duration, and overall survival metrics, all corroborated the primary findings, demonstrating consistent therapeutic benefit across multiple clinical parameters.

Drug Mechanism and Profile

Fanregratinib (HMPL-453) functions as a novel, selective, and orally bioavailable inhibitor targeting fibroblast growth factor receptors 1, 2, and 3 (FGFR 1/2/3). This targeted mechanism addresses the specific molecular alterations present in FGFR-driven cholangiocarcinoma cases, offering a precision medicine approach to this treatment-resistant indication. The company intends to unveil comprehensive trial results at an upcoming medical conference, providing the broader oncology community with detailed efficacy and safety insights.